文献速递妇科

子宫内膜神经内分泌癌:病程、治疗与结局

Neuroendocrine carcinoma of the endometrium: Disease course, treatment, and outcomes.
PubMed 文献 · Gynecol Oncol · 2019-09-10

基于美国国家癌症数据库2004至2015年数据,比较子宫内膜神经内分泌癌(NECE)与低分化子宫内膜样子宫内膜癌(EC)的病程与结局。NECE患者更常为非白人、分期更晚,更常接受辅助化疗但较少接受放疗,中位生存17个月 vs 144个月,5年生存率38.3% vs 68.8%,死亡风险比为2.32。

要点

  • NECE患者较低分化EC患者分期更晚、更常为非白人。
  • NECE患者更常接受辅助化疗(60.2% vs 29.6%),较少接受放疗(28.0% vs 47.6%)。
  • NECE中位生存17个月 vs EC 144个月,5年生存率38.3% vs 68.8%。

核心结论

  • NECE是一种罕见且侵袭性的子宫癌,与低分化EC相比,NECE患者分期更晚且生存期更短。

研究设计与样本

  • 使用美国国家癌症数据库(NCDB)识别2004至2015年间子宫内膜神经内分泌癌(NECE)患者和低分化子宫内膜样子宫内膜癌(EC)患者,比较两组临床、人口学和治疗特征,采用Kaplan-Meier生存曲线和多变量Cox比例风险回归模型分析肿瘤组织学与生存的关联。
  • 共纳入28,291例EC患者和364例NECE患者。

主要发现

  • NECE患者较EC患者更常为非白人且分期更晚。
  • NECE患者更常接受辅助化疗(60.2% vs 29.6%),但较少接受放疗(28.0% vs 47.6%)(两者P < 0.001)。
  • NECE中位生存17个月(95% CI,12-23),EC中位生存144个月(95% CI,140-148)。
  • NECE 5年生存率38.3%(95% CI,32.7-43.8%),EC 5年生存率68.8%(95% CI,68.2-69.4%)。
  • 多变量模型中,NECE较EC的死亡风险比为2.32(95% CI,1.88-2.88);限于I期时HR=1.62(95% CI,1.01-2.61),限于III期时HR=2.57(95% CI,1.88-3.53)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Neuroendocrine carcinoma of the endometrium (NECE) is a rare malignancy. We examined the natural history and outcomes of women with NECE compared to patients with poorly differentiated endometrioid endometrial cancer (EC). METHODS: The National Cancer Database (NCDB) was used to identify women with NECE and women with poorly differentiated EC from 2004 to 2015. Clinical, demographic, and treatment characteristics were compared between groups. Kaplan-Meier survival curves and multivariable Cox proportional hazard regression models were used to identify associations between tumor histology and survival. RESULTS: A total of 28,291 women with EC and 364 women with NECE were identified. Patients with NECE were more often non-white and presented with later stage disease compared to patients with EC. Women with NECE were more likely to receive adjuvant chemotherapy (60.2% vs. 29.6%), but were less likely to receive radiation (28.0% vs. 47.6%) (P < 0.001 for both). Median survival was 17 months (95% CI, 12-23) for NECE and 144 months (95% CI, 140-148) for EC. 5-year survival was 38.3% (95% CI, 32.7-43.8%) for NECE vs. 68.8% (95% CI, 68.2-69.4%) for EC. In a multivariable model, the hazard ratio for death for women with NECE compared to EC was 2.32 (95% CI, 1.88-2.88). Similar findings were noted when the analysis was limited to women with stage I (HR = 1.62; 95% CI, 1.01-2.61), and stage III (HR = 2.57; 95% CI, 1.88-3.53) neoplasms. CONCLUSIONS: NECE is a rare and aggressive uterine carcinoma. Compared to patients with poorly differentiated EC, patients with NECE present with later stage disease and have decreased survival.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Schlechtweg K, Chen L, St Clair CM, et al. Neuroendocrine carcinoma of the endometrium: Disease course, treatment, and outcomes. Gynecol Oncol. 2019. PMID: 31519319. doi:10.1016/j.ygyno.2019.09.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。